ABSTRACT
INTRODUCTION
Valvular heart disease (VHD) is an important cause of reduced functional capacity, heart failure, arrhythmia, recurrent hospital admission, and early mortality. The combination of an ageing population, earlier diagnosis and greater availability of surgical and percutaneous interventions heralds a major increase in the healthcare resources required for its optimal management. (1, 2) There is therefore a pressing need to better understand the contemporary clinical and epidemiological characteristics of VHD, particularly in the elderly population.
Previous studies have either been hospital based (3) or retrospective in design (4, 5) and thus subject to significant selection biases. Broader epidemiological studies provide limited data and there are no contemporary prospective large-scale population-based studies specific to VHD in developed countries. Available retrospective data demonstrate an increasing prevalence with age, predominantly as a result of degenerative pathophysiology.(3-5) A major increase in the prevalence of VHD would therefore seem an inevitable consequence of the anticipated increase in the number of older people in the population. Reliable contemporary data demonstrating the prevalence of VHD are an essential requirement for researchers and clinicians to improve understanding of its underlying pathophysiology, risk factors, and natural history; and for policy makers and economists to plan the provision of health services for both surgical and percutaneous interventions and long term medical care.
Accordingly, we established a large prospective study to provide a unique populationbased evaluation of the contemporary clinical and epidemiological characteristics of VHD and create well defined and carefully phenotyped cohorts with individual valve lesions for future study. Herein, we present a cross-sectional analysis of the population prevalence of undiagnosed and known VHD in the first 2500 participants and quantify the community prevalence of milder forms of VHD for the first time.
METHODS
The OxVALVE Population Cohort Study (OxVALVE-PCS) is an ongoing prospective cohort study conducted in Oxfordshire, United Kingdom. Methodological details have been previously reported elsewhere. (6) In brief, subjects aged 65 years and older without known VHD who were registered with one of five primary care medical centres were invited to participate. Younger subjects were excluded since (i) previous retrospective studies have demonstrated that the prevalence of VHD is low in those aged less than 65 years,(4) and (ii) uptake of community screening was likely to be low in those with work or family commitments. The participating medical centres were representative of the local population demographics and selected for the availability of accurate patient databases with comprehensive search facilities.
Subjects with a previous diagnosis of VHD (identified using relevant National Health Service diagnostic Read codes) were not included in the echocardiographic study but their diagnostic data were collected to derive total prevalence. Exclusion criteria included terminal illness and immobility or general frailty precluding attendance (as judged by the general practitioner/family physician). Eligible subjects received an initial study invitation letter with a single follow-up reminder to non-respondersfurther contact with potential study participants was not permitted by the local research ethics committee which approved the study. All participants provided written informed consent.
Participant assessment
An investigating physician or British Society of Echocardiography (BSE) accredited sonographer undertook clinical and transthoracic echocardiographic assessment in the participant's local medical centre. Socioeconomic class (SEC) was determined using Index of Multiple Deprivation (IMD) scores based upon home address postcode. Each SEC corresponds to 20% of the national population (with SEC1/SEC5 denoting the least/most deprived quintiles, respectively).
Diagnostic criteria
The primary outcome was a finding of mild or more severe left sided VHD or moderate or more severe right sided VHD. Valve anatomy, physiology and severity of VHD were defined according to BSE criteria (7) and international guidelines. (8, 9) Aortic sclerosis (AoScl) was defined according to 2009 European Association of Echocardiography/American Society for Echocardiography guidelines (9) -thickening and focal calcification of the aortic valve leaflets, with normal or near normal cusp mobility and maximum aortic transvalvular velocity ≤2.5 m/s. Aortic stenosis (AS) was defined as aortic valve thickening or calcification with a maximum aortic transvalvular velocity >2.5m/s.
Statistical analysis
Participants were stratified by age and gender to explore the prevalence of VHD and Kingdom census) using gender-specific 5-year age-bands,
RESULTS

Demography
Initial screening of primary healthcare records in study centres demonstrated that 2.9% of potential participants aged 65 years and older were deceased, 3.1% were no longer registered with the practice, and 4.9% had a pre-existing diagnosis of VHD. A further 13.2% were excluded from the echocardiographic study for other reasons (e.g.
cognitive decline, terminal non-cardiac disease or severe immobility). Study uptake amongst the remaining potential study population in the first practice to complete recruitment was 53%, consistent with previous community-based echocardiographic screening studies for cardiovascular disease (Supplemental Figure 1) . (10, 11) In the first 2500 enrolled participants, the mean age (SD) was 73 (6) years and 51.5%
were female ( 
26).(13)
The vast majority (97.4%) of the study cohort (excluding those with known VHD)
had minimal or no symptoms with only 2.6% (65/2500) in New York Heart Association Class III/IV.
Prevalence of valvular heart disease
OVERALL
Newly detected (predominantly mild) VHD was identified in just over half (50.8%) of this large asymptomatic population (Table 2, Figure 1 ). The most common valve lesion was aortic sclerosis (AoScl, 34% of those with newly detected VHD), followed by mitral regurgitation (MR; mild 19.8%, moderate/severe 2.3%) and aortic regurgitation (AR; mild 13.6%, moderate/severe 1.6%). Aortic stenosis (AS), the most prognostically significant manifestation of VHD, was newly diagnosed in 1.3% of participants at a mean age of 77.3 (7.0) years in men and 75.6 (7.2) years in women. A bicuspid aortic valve was found in only 8 (0.3%) participants, reflecting the age of the study cohort and the fact that clinical manifestations of this condition usually present in the fifth or sixth decades.
CLINICALLY SIGNIFICANT VALVULAR HEART DISEASE Clinically significant (moderate or severe) VHD was newly diagnosed in 6.4% of participants. Addition of the further 4.9% of subjects with pre-existing VHD from the overall study cohort (assuming that moderate or severe VHD would result in a clinical diagnosis) created a derived total population prevalence of moderate or severe VHD of 11.3%.
RIGHT-SIDED VALVULAR HEART DISEASE Significant right-sided VHD was less common. In addition to moderate/severe tricuspid regurgitation (2.7%), moderate pulmonary regurgitation was found in 7/2500 participants (0.3%). There were none with tricuspid or pulmonary stenosis.
MULTIVALVE DISEASE
Multiple valve lesions were identified in over one third (38.5%) of the study population, affecting 47% of those with AoScl, 58% with MR, and 81% with AR ( Figure 2 ).
Association with clinical variables and socioeconomic class
Participants with newly detected VHD were on average 2.4 years older than those without ( We explored associations with clinical characteristics using multiple regression ( Figure 3A , Supplemental Table 1 ). After removal of non-significant variables, VHD was associated with older age, more deprived SEC, current or previous atrial fibrillation (AF), and higher systolic blood pressure. There was no association with gender. Conversely, current smoking, higher heart rate, diastolic blood pressure and body mass index were associated with a lower prevalence of VHD.
Restricting this analysis to subjects with newly diagnosed clinically significant (moderate or severe) VHD, there was an association with older age, current or previous AF, prior smoking and lower body mass index ( Figure 3B ). In this smaller subset there was no SEC association. 
Population projections
Combining our data concerning pre-existing and newly diagnosed VHD (and assuming no change in age and gender-specific prevalence), we predict a substantial Although progression of AoScl to AS is slow and affects only a minority of individuals, (19, 20) it is now accepted that AoScl is associated with adverse outcome over long term follow up and an independent marker of cardiovascular risk. Table 2 ) and previous echocardiography demonstrating associated VHD would have led to exclusion of this group from our echocardiographic study.
Variation in the prevalence and outcomes of coronary artery disease and stroke according to SEC is well described (28) The unique OxVALVE-PCS cohort will provide a platform for future studies examining long-term outcomes and cross-sectional associations of VHD in its earliest stages, enabling accurate assessment of the rate of progression in the community, exploration of genetic and biomarker associations, and elucidation of factors involved in the pathogenesis of this increasingly common condition.
Limitations
The present study has inevitable limitations. Although uptake was over 50% (despite We also recognise that our study cohort (mean IMD score 11.68) and the overall Comparison of our cohort with other UK populations would be of value and such collaborative studies are planned within our future research programme.
Conclusions
OxVALVE-PCS is the first population-based study worldwide aimed specifically at the community detection of VHD. In a large cohort of 2500 elderly subjects we 
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None. Table 2 . New diagnosis of valvular heart disease. Number of study participants (% of total cohort) with newly diagnosed valvular heart disease (there were no cases of tricuspid or pulmonary stenosis). VHD = valvular heart disease. * Mild calcific aortic valve disease refers to the combined number with aortic sclerosis and mild aortic stenosis. excluded from participation in the present study due to a prior diagnosis of valvular heart disease. Undiagnosed estimates are based on the number with newly diagnosed significant valvular heart disease in OxVALVE-PCS.
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